ENHERTU® Plus Pertuzumab Approved in the U.S. as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Br…

ENHERTU Plus Pertuzumab Approved in the U.S. for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer ...

Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Exdensur ...
Investing.com India

DBV Technologies stock soars after positive Phase 3 trial results

Investing.com -- DBV Technologies (NASDAQ:DBVT) stock soared 65.2% in after-hours trading Tuesday following the announcement of positive topline results from its Phase 3 VITESSE trial for the VIASKIN ...
Investing.com Philippines

DBV stock soars after Viaskin Peanut meets primary endpoint in trial

Investing.com -- DBV Technologies stock surged 30% after the company announced positive results from its Phase III VITESSE clinical trial for VIASKIN Peanut, a treatment for peanut allergies in ...
eLife

Niche exclusion of a lung pathogen in mice with designed probiotic communities

This study reports a valuable method to predict the capacity of a candidate probiotic bacterium to metabolically outcompete a bacterial pathogen in the ecological niche of the murine respiratory tract ...
AOL

MIT report: 95% of generative AI pilots at companies are failing

Good morning. Companies are betting on AI—yet nearly all enterprise pilots are stuck at the starting line. The GenAI Divide: State of AI in Business 2025, a new report published by MIT’s NANDA ...